TY - JOUR
T1 - Plasminogen activator inhibitor-1 and tissue plasminogen activator and incident AF
T2 - Data from the PREVEND study
AU - Mulder, Bart A
AU - Geelhoed, Bastiaan
AU - van der Harst, Pim
AU - Spronk, Henri M
AU - Van Gelder, Isabelle C
AU - Asselbergs, Folkert W
AU - Rienstra, Michiel
N1 - Funding Information:
The PREVEND study was supported by the Dutch Kidney Foundation (Grant E0.13 ) and the Netherlands Heart Foundation (Grant NHS2010B280 ). We acknowledge the support from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation , CVON 2014-9 : Reappraisal of Atrial Fibrillation: interaction between hyperCoagulability, Electrical remodeling, and Vascular destabilization in the progression of AF (RACE V) to MR, ICvG.
Funding Information:
Folkert W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre.
Funding Information:
Folkert W. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre .
Publisher Copyright:
© 2018 The Authors
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Background: Tissue-type plasminogen activator (TPA) and plasminogen activator inhibitor-1 (PAI-1) have been shown to be associated with increased risk for stroke, however, the association with incident atrial fibrillation (AF) is unknown. Methods: We examined 8265 individuals included in the PREVEND study. In all subjects, PAI-1 and TPA plasma/serum levels were measured using an ELISA kit. By means of univariate and multivariate analyses the association with incident AF was assessed. Results: Mean age was age 49 ± 13 years, and 50% were women. Of the 8265 patients free of AF at baseline, 267 (3.2%) patients developed incident AF during a mean follow-up of 9.7 ± 2.4 years. Baseline median levels of PAI-1 and TPA were 72.4 ng/ml and 3.1 ng/ml, respectively. In univariate analyses PAI-1 (Hazard ratio [HR] 1.10 95% Confidence interval [CI] 1.04–1.16, p < 0.001) and TPA (HR 1.05, 95% CI 1.01–1.08, p = 0.014) were associated with incident AF. However, after multivariate adjustment for age, sex, antihypertensive drugs, stroke, heart failure, myocardial infarction, diabetes mellitus, peripheral arterial disease, smoking, NT-proBNP, alcohol consumption, body mass index no significant association was found. Conclusion: In this community-based cohort, PAI-1 and TPA levels were not associated with incident AF.
AB - Background: Tissue-type plasminogen activator (TPA) and plasminogen activator inhibitor-1 (PAI-1) have been shown to be associated with increased risk for stroke, however, the association with incident atrial fibrillation (AF) is unknown. Methods: We examined 8265 individuals included in the PREVEND study. In all subjects, PAI-1 and TPA plasma/serum levels were measured using an ELISA kit. By means of univariate and multivariate analyses the association with incident AF was assessed. Results: Mean age was age 49 ± 13 years, and 50% were women. Of the 8265 patients free of AF at baseline, 267 (3.2%) patients developed incident AF during a mean follow-up of 9.7 ± 2.4 years. Baseline median levels of PAI-1 and TPA were 72.4 ng/ml and 3.1 ng/ml, respectively. In univariate analyses PAI-1 (Hazard ratio [HR] 1.10 95% Confidence interval [CI] 1.04–1.16, p < 0.001) and TPA (HR 1.05, 95% CI 1.01–1.08, p = 0.014) were associated with incident AF. However, after multivariate adjustment for age, sex, antihypertensive drugs, stroke, heart failure, myocardial infarction, diabetes mellitus, peripheral arterial disease, smoking, NT-proBNP, alcohol consumption, body mass index no significant association was found. Conclusion: In this community-based cohort, PAI-1 and TPA levels were not associated with incident AF.
KW - PAI-1
KW - TPA
KW - Atrial fibrillation
UR - http://www.scopus.com/inward/record.url?scp=85051388433&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2018.08.029
DO - 10.1016/j.ijcard.2018.08.029
M3 - Article
C2 - 30115418
SN - 0167-5273
VL - 272
SP - 208
EP - 210
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -